Compare National Beverage Corp. (FIZZ) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs Gilead Sciences, Inc. — how do they compare? National Beverage Corp. trades at $30.61 (market cap $2.89B), while Gilead Sciences, Inc. trades at $151.28 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 63.1× National Beverage Corp.'s market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while National Beverage Corp. pays none. Which is the better fit depends on your goals — on Pluang, investors hold National Beverage Corp. for 33 Days and Gilead Sciences, Inc. for 111 Days on average.
| FIZZ | GILD | |
|---|---|---|
Market Cap | $2.89B | $182.40B |
Volume | 553,950 | 4,469,821 |
Sector | Consumer Staples | Health |
52-Week High | $37.73 | $155.80 |
52-Week Low | $29.20 | $116.74 |
Typical Hold Time | 33 Days | 111 Days |
Enterprise Value | $2.84B | $205.46B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
National Beverage Corp. (FIZZ) trades at $30.36, up 2.57% today, showing mixed signals with a bullish technical outlook but bearish analyst sentiment. The stock faces margin pressure with recent earnings misses and declining revenue growth, though profitability metrics remain strong with 14.81% net margin and 40.13% ROE. Recent news highlights institutional buying and a $3.25 special dividend payment.
FIZZ presents a cautious investment case with strong profitability offset by growth challenges. The company's high ROE and solid margins provide fundamental support, but consecutive earnings misses and tariff-related margin compression create near-term headwinds. Analyst consensus leans bearish with 50% sell ratings, suggesting limited upside potential despite technical strength.
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
